Results: Using IHC, we found in normal adult tissue that INSM1 expression was highly restricted to nuclei of NE cells and tissues. INSM1 was not detected in any adult

Conclusions: INSM1 expression was significantly increased in neoplastic vs nonneoplastic tissue. Furthermore, among midgut GI-NENs, neoplasms with known metastases showed significantly higher expression than those that had not yet metastasized.
Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplasms, derived from neuroendocrine (NE) cells in diverse tissues. Collectively, NENs have an estimated incidence of 2.5 to 5 per 100,000 people per year, 1 with gastrointestinal NENs (GI-NENs, formerly carcinoids) comprising roughly two-thirds of the total. It is often difficult to predict which tumors will go on to metastasize.
NENs share histologic and biochemical features with each other but also with neuroepithelial tumors exhibiting neural (rather than glial) features (eg, medulloblastoma). Neuroepithelial tissues and their neoplastic derivatives (eg, medulloblastoma, retinoblastoma, and olfactory neuroblastoma) share many developmental and biochemical properties with their NE counterparts, often expressing common markers such as chromogranin and synaptophysin, and regulated by similar transcription factors, such as ASCL1, NGN3, and NEUROD1.
INSM1 is a transcription factor involved in the terminal steps of these developmental pathways. Originally isolated Upon completion of this activity you will be able to:
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© American Society for Clinical Pathology via a subtraction library of human insulinoma and glucagonoma samples, from which it took its name (insulinoma associated protein 1), INSM1 has since been detected in several tumor types in humans, mice, and rats and is thought to be largely absent from healthy adult tissues. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The human INSM1 protein binds both to DNA and to other proteins, most notably cyclin D1. [13] [14] [15] By binding cyclin D1, INSM1 directly arrests progression of the cell cycle. The binding of cyclin D1 also directly mediates the transcriptional effects of INSM1. Thus, INSM1 functionally links transcriptional activity to cell cycle arrest. Studies in knockout mice and in human cells altering or ablating expression of INSM1 have reaffirmed a critical role in the appropriate development of neural and NE tissues. 16 Effects on both terminal cellular differentiation and cellular proliferation have been observed in the pancreas, 4, 6, [16] [17] [18] enteroendocrine cells, 6 autonomic nervous system, 8 central nervous system, 9,10 olfactory epithelium, 19 and pituitary. 11 Laboratory studies have associated INSM1 with a number of NE and neuroepithelial tumors: insulinomas (for which the gene is named), pituitary adenomas, medullary thyroid carcinomas, 2 pheochromocytomas, 20 hypothalamic hamartomas, 17 small cell lung cancers (SCLCs), 2,21-23 and medulloblastomas. [24] [25] [26] Lan et al 21 reported that INSM1 was expressed in 97% of SCLC cell lines, with a high degree of concordance with the NE markers chromogranin A and l-3,4-dihydroxyphenylalanine decarboxylase. In non-SCLC, INSM1 was found only in 13% of lines and only in those that also express other NE markers. INSM1 was highly associated with medulloblastoma, 26 with highest expression noted in the desmoplastic variant. INSM1 was also detected in a screen for genes with increased expression in malignant pheochromocytomas. 20 A recent reanalysis of microarray expression data identified upregulation of INSM1 in small intestinal GI-NENs. 27 Despite these prior studies, INSM1 has not been evaluated as a broadspectrum marker for clinical use in human disease.
We examined a large series of NE tissues and NENs for INSM1 expression and found that it was highly expressed in NE cells and NENs. Expression of INSM1 was not present in most adult non-NE tissue. Furthermore, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis showed that INSM1 messenger RNA (mRNA) expression correlated with metastatic disease in GI-NENs.
Materials and Methods
Immunohistochemistry and Western Blot
The study comprised 129 cases of NE and neuroepithelial neoplasms, 27 control neoplasms, and five neoplasms Technologies, Coralville, IA), yielding a 139-base pair product. Peptidylprolyl isomerase A (PPIA) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels were used to normalize the relative quantity of the INSM1 transcript in different FFPE tissue samples (PPIA and GAPDH primers from Qiagen). Each specimen was tested for DNA contamination by performing a direct amplification on the purified mRNA without reverse transcription. Samples that amplified were presumed to be contaminated with DNA and were treated with DNAse and reevaluated. Once samples were determined to be free of DNA contamination, they were amplified by qRT-PCR according to standard protocols and methods. 28 with the anti-INSM1 antibody applied at a concentration of 1:10,000, incubated at 4°C overnight and an HRP-conjugated goat anti-mouse secondary antibody applied at a concentration of 1:2,000. The specimen was considered negative if fewer than 1% of cells showed positive nuclear staining, focally positive if 2% to 19% of cells showed positive nuclear staining, and frankly positive if 20% of cells or greater showed positive nuclear staining. GI-NEN specimens were also semiquantitatively evaluated for intensity of staining on a scale of 0 to 3+.
qRT-PCR
The qRT-PCR assay for INSM1 expression was developed on control tissue from the UWHC autopsy archives. Infant cerebellum was used as a positive control, and kidney from the same patient was used as a negative control. Samples were prepared using established protocols for RNA extraction from formalin-fixed, paraffin-embedded (FFPE) tissue. Following deparaffinization using CitriSolv (Thermo Fisher Scientific) and ethanol, total RNA was extracted from a total of three 12-mm sections of FFPE tissue using the RNEasy FFPE Kit (73504; Qiagen, Valencia, CA). Samples were treated with DNAse using RQ1 RNase Free DNase (M6101; Promega, Madison, WI). Aliquots (5 mL) from total RNA were reverse transcribed and real-time PCR amplified concurrently using the SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit RNA was purified and evaluated as described above.
INSM1 fold-changes (DDCPs) were calculated in duplicate vs both GAPDH and PPIA. Pearson's correlation coefficient (R) was calculated for each data set to assess reproducibility of results. GAPDH was slightly more reproducible (R = 0.89 vs R = 0.88) and more reliably amplified (data not shown). Subsequent analyses calculated INSM1 DDCP with respect to GAPDH. All calculations and statistical analyses were performed using Microsoft Excel (Microsoft, Redmond, WA).
Results
To demonstrate the utility of IHC for detecting INSM1 in FFPE human tissue, we first confirmed that INSM1 is detected in FFPE tissue types in which INSM1 expression is recognized or suspected, which occur predominantly during embryonic and fetal development. Using autopsy tissue, we confirmed INSM1 expression in developing neuroepithelial and NE tissues. In fetal tissues, INSM1 was detected in GI epithelium and enteric nervous system (Image 1A), pancreas (Image 1B), cerebellum (Image 1C), thyroid, respiratory epithelium, and thymus. The cellular expression pattern was nuclear, and background staining was minimal. In parallel, we used postnatal cerebellum to demonstrate quantitative detection of INSM1 by qRT-PCR in FFPE tissue. INSM1 amplified reliably from cerebellum but not from kidney of the same decedent. To determine the sensitivity and specificity of IHC for INSM1, we examined a spectrum of neuroectodermal neoplasms ( (Table 1) .
We surveyed normal tissue from all slides examined by IHC for INSM1 expression, and in the nonneoplastic, non-NE tissues, we detected no expression of INSM1 (Table 2) . Notable tissues in which INSM1 was not detected included lymphoid tissue (n = 66 specimens), nerve and central nervous system tissue (n = 30), exocrine pancreas (n = 14), pneumocytes (n = 10), sustentacular cells of adrenal medulla and paraganglia (n = 8), thyroid (n = 8), and adrenal cortex (n = 7). In a handful of nonneoplastic adult cell types, we did © American Society for Clinical Pathology detect INSM1 expression. These are all NE tissues, including adrenal medulla, pancreatic islets, and GI enterochromaffin cells ❚Image 3❚ and ❚Image 4❚. We also identified INSM1-expressing cells in occasional small clusters within normal bronchial epithelium and in occasional individual cells in nonneoplastic prostate glands (data not shown). INSM1 was not detected in normal ductal or glandular epithelia from other sites (breast, urothelium, pancreas, endometrium, skin adnexa, renal epithelium; n = 37).
We compared IHC for INSM1 directly with the traditional, cytoplasmic NE markers chromogranin and synaptophysin (Image 4). In a case with roughly comparable staining from all three markers, the distinct, nuclear pattern of INSM1 clearly distinguishes it from the other two markers (Image 4). In addition, INSM1 appears more specific to NE cells than synaptophysin (compare the epithelial and stromal staining in Image 4D with that in Image 4A). In our data set (n = 30) of GI-NENs stained for all three markers, INSM1 is quite comparable in sensitivity and specificity to both chromogranin and synaptophysin ❚Table 3❚.
Expression of INSM1 was detected by qRT-PCR in tissue from GI-NENs, with the average GI-NEN showing a 14.69-fold increase in expression of INSM1 relative to nonneoplastic tissue (P < .005). With a threshold level taken as 1-fold expression (ie, no increase in expression compared to the negative control), qRT-PCR detects GI-NENs with a Several specimens had INSM1 expression levels orders of magnitude higher than the mean. These specimens were all found in derivatives of the embryonic foregut (n = 4 specimens, all from the stomach or esophagus). This prompted evaluation of INSM1 expression with respect to the embryonic site of origin. Expression levels of INSM1 in the foregut were consistently and significantly higher than those in the midgut or hindgut (43-fold increase in expression vs 4-and 6-fold increases in expression, respectively; P < .01) ❚Figure 1C❚. When the embryonic sites are then subdivided based on malignant behavior, tissue from the embryonic foregut expresses INSM1 at dramatically higher levels in every category, including in nonneoplastic tissue; the average fold increase in expression of INSM1 in nonneoplastic tissue of the foregut, midgut, and hindgut is 1.29-fold, 0.26-fold, and 0.30-fold, respectively. Moreover, the number of specimens in the foregut and hindgut (n = 24 and 23, respectively) was not sufficient for these categories to achieve statistical significance on their own (P = .22 and .15 by ANOVA, respectively). Only the pattern of INSM1 expression in the midgut achieves statistical significance (n = 60, P < .05 by ANOVA) ❚Figure 1D❚. The low numbers of foregut specimens along with the significantly higher expression of INSM1 suggest that there may be underlying biologic differences between sites within the GI tract, and these differences may skew our analysis.
Since the numbers of specimens from the foregut and hindgut were too low to achieve significance, we focused specifically on GI-NENs arising from the midgut to determine whether level of expression of INSM1 correlates with malignant behavior. Among GI-NENs of the midgut, the average fold-change of INSM1 in primaries with known metastases was nearly twice that of primaries without known metastases ( Figure 1D ; P < .05 by t test). To determine whether this difference achieved clinical significance, we directly compared the expression level of INSM1 for the samples. Among primary lesions of the midgut, the mean increase in INSM1 expression is 4.8-fold ❚Figure 1E❚. Using this as a threshold, expression of INSM1 above 4.8-fold predicts nodal or distant metastasis with 81.3% specificity and 47.6% sensitivity.
Semiquantitative evaluation of IHC for INSM1 correlated with average fold-change of INSM1 mRNA expression by qRT-PCR ❚Image 5❚ and ❚Figure 2❚. When evaluated on a scale of 0 to 3+, this correlation is not statistically significant (correlation coefficient of 0.46; P = .26 by ANOVA). However, when evaluated as weak staining (0 or 1+; mean INSM1 fold-increase of 1.03) vs strong staining (2+ or 3+; mean INSM1 fold-increase of 7.23), the difference in the mean fold-increase in expression of INSM1 is highly significant (P < .005 by t test). Among the weakly staining specimens, no specimen had an increase greater than 3.25-fold.
❚Image 3❚ Immunohistochemistry for INSM1 is largely specific for neuroendocrine and neuroepithelial neoplasms. INSM1 is not detectable in most nonneoplastic adult tissues, with a few notable exceptions: pancreatic islets (A, ×200), adrenal medulla (B, ×200), and enterochromaffin cells of the gastrointestinal epithelium (see Image 4B and Image 5).
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Discussion
We found that INSM1 was consistently expressed in NENs and in related neuroepithelial neoplasms (such as medulloblastoma). This expression was highly restrictedin the adult, we detected INSM1 in only a handful of normal NE tissues and not at all in tissues outside the NE system. In neoplasms, INSM1 expression was similarly restricted. In addition, qRT-PCR analysis correlated quantitative INSM1 expression with metastatic disease in GI-NENs.
We readily detected INSM1 by IHC in the nuclei of fetal neural and NE tissues, including pancreas, thyroid, GI and tracheal epithelium, enteric neurons, and cerebellum, which agrees with previous reports. 3, 6, 8, 11, 19, 29 Regarding expression of INSM1 in adults, most of the previous literature has been restricted to animal models or cell culture. [2] [3] [4] 6, 8 By IHC, we confirmed expression of INSM1 in a handful of nonneoplastic adult cell types in humans: NE cells of the gastrointestinal tract, pancreatic islets, adrenal medulla, and rarely small nests in bronchial epithelium and individual cells of prostatic glandular epithelium. We did not detect INSM1 expression in any nonneoplastic, non-NE adult tissue.
Applying anti-INSM1 IHC to neoplasms, we detected INSM1 in some proportion of cells in nearly all NENs and all neuroepithelial neoplasms examined. The notable ❚Image 4❚ Immunohistochemistry (IHC) for INSM1 compares well with traditional neuroendocrine (NE) markers. Comparative staining of a rectal gastrointestinal NE neoplasm (A, H&E, ×100) reveals robust expression of INSM1 (B, ×200), along with both chromogranin A (C, ×200) and synaptophysin (D, ×200), the more traditional markers of neoplastic NE tissue. In this case, INSM1 appears coexpressed with chromogranin and synaptophysin in nearly all neoplastic cells. In contrast to other NE IHC markers, INSM1 expression is specifically nuclear. 30 INSM1 has not been specifically investigated in parathyroid tissue; perhaps the specialized endodermal derivation of this NE tissue makes use of an alternative transcriptional mechanism. With parathyroid neoplasms excluded, INSM1 was detectable by IHC in 92.7% of NE and neuroepithelial neoplasms generally, with possible variation according to specific category of neoplasm. Importantly, INSM1 was not detectable in most non-NE, nonneuroepithelial neoplasms. Indeed, outside of NE and neuroepithelial neoplasms, INSM1 was detected in only two scenarios: neoplasms with NE differentiation recognized by other means (four of five such specimens) and in breast carcinoma from one patient. For practical purposes, IHC for INSM1 distinguishes neoplastic NE cells from nearby tissue that may have a similar appearance on H&E, such as lymphoid tissue. In addition, although we do detect INSM1 expression in a handful of nonneoplastic adult NE tissues, these are infrequent and usually readily distinguishable from neoplasms of these tissues.
We found that INSM1 compares well with traditional markers of NE tissue. In contrast with most other markers of NE tissue, INSM1 is a transcription factor with nuclear expression. This feature offers advantages over cytoplasmic Direct quantification of the INSM1 gene product offers a more direct assay with which to correlate the clinicopathologic properties of individual neoplasms. To quantify the expression level of INSM1, we developed a qRT-PCR assay for expression of INSM1 mRNA. GI-NENs are the most common of the NENs but lack good markers correlating with propensity for distant or nodal metastases. To determine if the quantitative expression of INSM1 correlates with malignancy, we applied our assay to GI-NENs. We found that expression levels were not consistent between different portions of the GI tract. In both neoplasms and control tissue, INSM1 is expressed at much higher levels in derivatives of the embryonic foregut. It is likely that some combination of greater numbers, higher turnover, or more NE activity in the enterochromaffin cells of the foregut contributes to the higher levels of expression. Importantly, despite comparatively low numbers of specimens from the foregut, the difference in expression is enough to skew a more general analysis of GI-NENs.
Restricting our analysis to GI-NENs that arise in derivatives of the midgut, we found that overexpression of INSM1 correlated with the propensity of the primary tumor to metastasize. Furthermore, our data suggest that increased expression of INSM1 by a level of 4.8-fold or greater is 81.3% specific to neoplasms with a known metastasis. From a prognostic standpoint, this was likely a conservative estimate; one of the primary specimens with expression of INSM1 elevated above this threshold shows histologic evidence of aggressive behavior (involvement of the muscularis propria) on H&E, despite not having a proven metastasis. In addition, the patients in this study have not been followed prospectively, and it is likely that some of the patients may develop metastases over time. It is not clear whether increased expression of INSM1 is a cause or a consequence of pathology. No oncogenic mutations within the INSM1 gene have been identified to date. Nevertheless, elevated expression of INSM1 in several tumor types, now including GI-NENs, suggests potential prognostic utility for INSM1. ❚Figure 1❚ Overexpression of INSM1 messenger RNA in gastrointestinal neuroendocrine neoplasms (GI-NENs) correlates with metastasis. INSM1 is overexpressed in GI-NENs but not in nonneoplastic tissue (A). The mean DDCP for GI-NENs (fold-change of 14.69) is 34 times greater than the mean DDCP for nonneoplastic tissue (fold-change of 0.43; P < .02 by t test). Using a DDCP threshold of 1.00 to define overexpression, use of quantitative reverse transcriptase polymerase chain reaction for INSM1 to detect GI-NENs has a sensitivity of 80.6% and specificity of 92.3%. When specimens are categorized by degree of malignancy, a trend emerges directly correlating overexpression of INSM1 with metastatic potential, although this pattern does not achieve statistical significance (B; P = .17 by analysis of variance [ANOVA]). Expression of INSM1 in GI-NENs varies significantly between those that arise from derivatives of the embryonic foregut, midgut, and hindgut (C; P < .01 by ANOVA). Average fold-change of INSM1 in the foregut is highest, at nearly 43-fold, despite consisting of only 24 specimens. In contrast, GI-NENs derived from the midgut showed a mean increase in INSM1 expression of 4.12-fold (65 specimens). When specimens are subdivided based on metastatic behavior in addition to embryonic derivation, only the midgut specimens (D) achieve statistical significance (P = .22 in the foregut; P < .05 in the midgut; P = .15 in the hindgut by ANOVA). The average fold-increase of INSM1 in midgut GI-NENs with known metastasis is significantly higher than that of GI-NENs without known metastasis (6.11 vs 3.19, respectively; P < .05 by t test). Scatterplot of the actual fold-change for individual specimens (E) reveals that midgut GI-NENs without metastasis rarely (three of 16 specimens) express INSM1 at greater than a 4.8-fold increase in expression (dashed line). In contrast, half of primaries with metastasis (10 of 21 specimens) demonstrate increased expression at greater than 4.8-fold. Increased expression of INSM1 by greater than 4.8-fold has a sensitivity for predicting metastasis of 47.6% and a specificity of 81.3%. Error bars reflect SEM. 
